Science-backed peptide guides, protocols, and research breakdowns
The first randomised controlled trial of hyperbaric oxygen therapy for long COVID demonstrated significant improvement in cognitive, physical, and quality-of-life measures after 40 sessions at 2.0 ATA.
Monoplace and multiplace chambers deliver equivalent HBOT at the pressure level, but differ substantially in logistics, cost, patient experience, and clinical workflow.
Soft-shell "mild HBOT" at 1.3 ATA is marketed widely for wellness and recovery. The clinical evidence is thinner than most promotional material suggests.
The Undersea and Hyperbaric Medical Society maintains the authoritative list of 14 approved HBOT indications. Here is a plain-language overview of each.
ATA — atmospheres absolute — is the pressure unit that defines every HBOT protocol. Here is what the number means, how it maps to clinical practice, and why it matters.
Two fatal hyperbaric chamber fires in 2025 prompted an FDA Letter to Health Care Providers reinforcing manufacturer-use instructions, static control, and electronics exclusion.
The Undersea and Hyperbaric Medical Society released the 15th Edition of its Indications Manual in 2023, adding a dedicated chapter on HBOT dosing and a new approved indication.
The Swedish HOT-LoCO phase II RCT (2025, Lancet Respir Med) found no significant benefit of 10 HBOT sessions vs sham in long COVID — fueling the dose debate against Efrati's 40-session protocol.
A 2024 Zilberman-Itskovich RCT (Nature Scientific Reports) found 60 sessions of HBOT at 2.0 ATA produced significantly greater symptom improvement than pregabalin+duloxetine in fibromyalgia patients with a history of childhood sexual abuse.